Mallinckrodt sells contrast media and delivery systems business to Guerbet for $270 million.

Mallinckrodt plc announced that it has entered into a definitive agreement under which it will sell its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million. For the first six months of fiscal 2015, sales of Mallinckrodt's CMDS business were $2101 million.Mallinckrodt's CMDS business manufactures and markets a comprehensive array of diagnostic imaging products engineered to work across the radiology suite � computed tomography, magnetic resonance imaging, X-ray and cardiac catheterization � as well as the company's urological imaging system and related components. The company's prefilled contrast media syringe was the first of its kind and, along with its contrast delivery systems, helps simplify contrast media injections and improve technologists' efficiency, while also helping to reduce or prevent certain patient risks.